MA51339A - Procédé de préparation de composés pyrimidinyl-4-aminopyrazole - Google Patents

Procédé de préparation de composés pyrimidinyl-4-aminopyrazole

Info

Publication number
MA51339A
MA51339A MA051339A MA51339A MA51339A MA 51339 A MA51339 A MA 51339A MA 051339 A MA051339 A MA 051339A MA 51339 A MA51339 A MA 51339A MA 51339 A MA51339 A MA 51339A
Authority
MA
Morocco
Prior art keywords
pyrimidinyl
preparation
aminopyrazole compounds
aminopyrazole
compounds
Prior art date
Application number
MA051339A
Other languages
English (en)
Inventor
Travis Remarchuk
Anantha Sudhakar
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA51339A publication Critical patent/MA51339A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051339A 2017-12-20 2018-12-19 Procédé de préparation de composés pyrimidinyl-4-aminopyrazole MA51339A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762608398P 2017-12-20 2017-12-20

Publications (1)

Publication Number Publication Date
MA51339A true MA51339A (fr) 2020-10-28

Family

ID=66994244

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051339A MA51339A (fr) 2017-12-20 2018-12-19 Procédé de préparation de composés pyrimidinyl-4-aminopyrazole

Country Status (14)

Country Link
US (2) US11834438B2 (fr)
EP (1) EP3727377B1 (fr)
JP (1) JP7284172B2 (fr)
KR (1) KR20200100757A (fr)
CN (1) CN112088003B (fr)
AU (1) AU2018392599A1 (fr)
BR (1) BR112020012611A2 (fr)
CA (1) CA3086182A1 (fr)
ES (1) ES2975958T3 (fr)
IL (1) IL275480B2 (fr)
MA (1) MA51339A (fr)
MX (1) MX2020006641A (fr)
SG (1) SG11202005752PA (fr)
WO (1) WO2019126383A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834438B2 (en) 2017-12-20 2023-12-05 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
CN115894456A (zh) * 2022-11-13 2023-04-04 药康众拓(江苏)医药科技有限公司 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
SG189043A1 (en) * 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
MX349556B (es) 2011-11-29 2017-08-03 Genentech Inc Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
US8791130B2 (en) 2011-11-29 2014-07-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
CA2850594C (fr) 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Derives aminopyrimidiniques utilises comme modulateurs de lrrk2
EP2785381B1 (fr) 2011-11-30 2016-05-18 F.Hoffmann-La Roche Ag Radioligands marqués par le fluor 18 et le carbone 11 pour une imagerie par tomographie par émission de positons (pet) pour lrrk2
CN104271569B (zh) 2012-05-03 2016-08-24 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
EP2844658B1 (fr) 2012-05-03 2019-03-20 Genentech, Inc. Dérivés de pyrazole aminopyrimidine en tant que modulateurs de lrrk2 destinés à être utilisés dans le traitement de la maladie de parkinson
US9238644B2 (en) * 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
WO2017156493A1 (fr) * 2016-03-11 2017-09-14 Denali Therapeutics Inc. Composés, compositions et procédés
US10829484B2 (en) * 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US11214565B2 (en) * 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
SI3472153T1 (sl) 2016-06-16 2022-01-31 Denali Therapeutics Inc. Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj
WO2018217946A1 (fr) 2017-05-24 2018-11-29 Denali Therapeutics Inc. Composés, compositions et procédés
PE20210157A1 (es) 2017-11-21 2021-01-26 Denali Therapeutics Inc Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion
US11834438B2 (en) 2017-12-20 2023-12-05 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
AR118641A1 (es) 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos

Also Published As

Publication number Publication date
IL275480A (en) 2020-08-31
CN112088003A (zh) 2020-12-15
MX2020006641A (es) 2021-01-08
BR112020012611A2 (pt) 2020-12-08
CN112088003B (zh) 2023-10-13
AU2018392599A1 (en) 2020-07-09
US20210009566A1 (en) 2021-01-14
EP3727377A4 (fr) 2021-08-18
KR20200100757A (ko) 2020-08-26
US11834438B2 (en) 2023-12-05
SG11202005752PA (en) 2020-07-29
ES2975958T3 (es) 2024-07-18
EP3727377B1 (fr) 2024-01-31
US20240158371A1 (en) 2024-05-16
JP2021506892A (ja) 2021-02-22
IL275480B2 (en) 2023-10-01
US12497387B2 (en) 2025-12-16
JP7284172B2 (ja) 2023-05-30
CA3086182A1 (fr) 2019-06-27
EP3727377A1 (fr) 2020-10-28
IL275480B1 (en) 2023-06-01
WO2019126383A1 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
EP3398960A4 (fr) Procédé de préparation du sermaglutide
MA54253A (fr) Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines
EP3349587A4 (fr) Procédé de préparation d'un composé antifongique
EP3500551A4 (fr) Procédé de préparation de biphényles substitués
MA42423A (fr) Procédé de préparation d'un revêtement
EP3766869A4 (fr) Procédé simple de préparation d'avibactam
EP3400197A4 (fr) Procédé améliore de préparation de bleu isosulfane
EP3696168A4 (fr) Procédé de préparation de 2-chloro-5-trifluorométhylpyridine
EP3539941A4 (fr) Procédé de préparation triméthylolpropane
EP3511313A4 (fr) Procédé de préparation de 1,3-cyclohexanediméthanol
EP3436425A4 (fr) Procédé de préparation amélioré de tartrate de butorphanol
EP3350154A4 (fr) Procédé amélioré de préparation de dichlorhydrate de trientine
EP3505525A4 (fr) Procédé de préparation de rubusoside
EP3727377A4 (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
EP3770239A4 (fr) Procédé de préparation de microcapsules
EP3981753A4 (fr) Procédé de préparation de triphénylchlorométhane
EP3444253A4 (fr) Procédé de préparation de ad-35
EP3455210A4 (fr) Procédé de préparation de boscalide
EP3733651A4 (fr) Procédé de préparation de calcobutrol
EP3359512A4 (fr) Procédé de préparation de bromures organiques
MA51870A (fr) Procédé pour la préparation de composés coupleurs de médicaments
EP3786152A4 (fr) Procédé de préparation de composé nitrile aromatique
EP3395786A4 (fr) Procédé de préparation de butadiène
EP3533856A4 (fr) Procédé de préparation d'hexadécahydropyrène